Pharmaceutical products

Tender description

This framework agreement is for the supply of unlicensed, aseptically compounded, ready to use medicines in syringe and infusion bags to NHS Scotland. The goods have been separated into four (4) categories, each of which is identified as a ‘Lot’. Full details of each lot is contained in section II.2 of this notice. Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses: Atezolizumab Cetuximab Doxorubicin Epirubicin Infliximab (Inflectra®), (Remicade®), (Remsima®) Nivolumab Pembrolizumab Pertuzumab The authority has awarded all presentations within this lot to a single supplier. Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses: Cyclophosphamide Fluorouracil Irinotecan Methotrexate Rituximab (Mabthera®), (Rixathon®), (Truxima®) The authority has awarded all presentations within this lot to a single supplier. Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses: Bortezomib Carboplatin Cisplatin Docetaxel Gemcitabine Oxaliplatin Trastuzumab (Herceptin®), (Herzuma®) Vincristine The authority has awarded all presentations within this lot to a single supplier. Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses: The molecules included in this lot are: Bevacizumab Cytarabine Infliximab (Zessly®) Insulin Methotrexate Natalizumab Nivolumab Paclitaxel Pemetrexed Tocilizumab Trastuzumab (Kanjinti®), (Ontruzant®) Trastuzumab Subcutaneous Vedolizumab. Each product line was treated as an individual lot and awarded as an unranked multi-supplier framework.